Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.

Raphael WurmMichael ReslStephanie NeuholdRudolf PragerHelmut BrathClaudia FrancesconiGreisa VilaGuido StrunkMartin ClodiAnton LugerRichard PacherMartin Hülsmann

Published in: Heart (British Cardiac Society) (2016)

Metformin is associated with beneficial cardiovascular outcomes in patients with diabetes only when (sub)clinical cardiovascular risk defined by NT-proBNP levels is present.

Keyphrases

left ventricular